Will Ebiefung

About the Author Will Ebiefung

Will Ebiefung studied finance and accounting at the University of Tennesee. He works as a freelance investment analyst focusing on equities with market caps below $100 million. In addition to writing, Will is a full-time investor focusing on web properties and debt-based securities.

A Glimpse Into Advanced Micro Devices, Inc. (AMD) Financial Analyst Day

Advanced Micro Devices, Inc. (NASDAQ:AMD) was a poor performer over the last few weeks; this due to soft guidance from last quarter’s earnings.

Aurinia Pharmaceuticals Inc (AUPH): Betting on the Home Team

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is an all or nothing bet. The company’s future depends on its only pipeline asset Voclosporin, a drug candidate …

Tesla Inc (TSLA): Re-Envisioning the Valuation

Tesla Inc (NASDAQ:TSLA) is often called overvalued, and if you look at the automaker’s revenue compared to its market cap, the stock is …

Valeant Pharmaceuticals Intl Inc (VRX) Legal Saga Illustrates Problems

Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) legal mess is a red flag for investors because the heavily indebted drugmaker hasn’t earmarked enough liquidity to …

Dryships Inc. (DRYS) Shows Improvement but the Outlook Is Not Encouraging

DryShips Inc. (NASDAQ:DRYS) continues to be one of the most controversial stocks on the market – a favorite of day traders and adrenaline …

Here’s Why Valeant Pharmaceuticals Intl Inc (VRX) Shares Skyrocket

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has reported mixed first quarter earnings on May 9th, and the market is reacting positively to the news. …

Should Investors Be Concerned About Facebook Inc’s (FB) Ads Business?

Last week, Facebook Inc (NASDAQ:FB) reported strong earnings results, beating EPS estimates by $0.18 and revenue estimates by $200 million – posting total revenues …

Gilead Sciences, Inc. (GILD) Continues to Fail, But the Stock Remains Cheap

Gilead Sciences, Inc. (NASDAQ:GILD) stock cratered after disappointing first quarter earnings.

Valeant Pharmaceuticals Intl Inc (VRX) Outlines Plan for Debt Management; EBITDA Stabilization Remains Uncertain

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) revealed the human side of its business at the company’s annual shareholder meeting held on May 2, 2017, …

DryShips Inc. (DRYS) Slides Into More Troubles

Multiple legal firms have launched investigations into the actions of DryShips Inc. (NASDAQ:DRYS), CEO George Economou, and Kalani Investments Limited over possible violations …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts